US Appeals court overturns Copaxone patents, while UK comes out in Teva's favor
This article was originally published in Scrip
Momenta Pharmaceuticals/Sandoz and Mylan Laboratories/Natco Pharmaceuticals can now plan to start selling generic Copaxone in May 2014 in the US market, around 18 months sooner than previously slated, after a federal appeals court declared several of the patents protecting Teva's multiple sclerosis drug to be invalid for being "indefinite" on 26 July.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.